Clinical Trials Browser

Phase 2 × Active not recruiting × spartalizumab × Clear all

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2 Active not recruiting

33 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Phase 2 Active not recruiting

19 enrolled

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT05522582 2024-10-26

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Phase 2 Active not recruiting

50 enrolled

Other solid neoplasm

Solid Tumors

NCT04301557 2024-04-23

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Phase 2 Active not recruiting

25 enrolled

GastrointestinalOther solid neoplasm

DMMR Colorectal Cancer

NCT04833387 2023-01-11

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms